Abacavir is an antiretroviral drug used to reduce human immunodeficiency virus (HIV) replication and decrease the risk of developing acquired immune deficiency syndrome (AIDS).
Introduction
Abacavir is an antiretroviral medication used for the treatment of human immunodeficiency virus (HIV) infection 1, 2 . It is a prodrug that is converted by the liver 3 to form the pharmacologically active compound carbovir 5-triphosphate 4 , an analogue of guanosine that targets HIV reverse transcriptase. Abacavir has been found to elicit a drug hypersensitivity reaction in up to 8% of treated patients 5, 6 , with hypersensitivity attributed to the prodrug itself 7, 8 . Symptoms of abacavir hypersensitivity syndrome (AHS) include fever, malaise, nausea, diarrhoea and skin rash, and the condition can be fatal in severe cases 9 . AHS is strongly associated with patients carrying a human leukocyte antigen (HLA)-B*57:01 allele, and is mediated by the activation of HLA-B*57:01 restricted CD8+ T-cells [10] [11] [12] . In contrast, hypersensitivity is not observed in patients carrying the closely related alleles HLA-B*57:03 (Asp114Asn; Ser116Tyr), HLA-B*57:02 (Asp114Asn; Ser116Tyr; Leu156Arg), and HLA-B*58:01 (Met45Thr; Ala46Glu; Val97Arg; Val103Leu) 7, 11 .
Mass spectrometry data characterizing the peptides eluted from HLA-B*57:01 cell lines treated with or without abacavir revealed abacavir alters the repertoire of peptides that are bound by HLA-B*57:01 7, 8, 13 . Crystallographic structures further revealed that abacavir binds non-covalently at the floor of the HLA-B*57:01 peptide-binding cleft, and makes contacts with F-pocket residues that differ in HLA-B*57:03, HLA-B*57:02 and HLA-B*58:01 7, 8 . In doing so, abacavir changes the chemistry and shape of the peptide binding cleft, thereby altering the repertoire of peptides that can be presented by HLA-B*57:01.
To further our understanding of AHS and the interactions between HLA-B*57:01, bound peptide, and abacavir, we performed a series of MD simulations of three HLA-B*57:01-peptide complexes in the presence (PDB IDs 3UPR 8 , 3VRI and 3VRJ 7 ) of abacavir, or with abacavir removed. We also performed MD simulations of three abacavir analogues (carbovir, didanosine, and guanosine) all bound to HLA-B*57:01, to serve as a comparison. These analogues are all chemically very similar to abacavir, but do not trigger a T-cell response 11 .
Our simulations show that abacavir can adopt a range of conformations in the HLA-B*57:01
antigen-binding cleft, as can the bound peptides. This suggests that conformational dynamics may play an underappreciated role in the recognition of HLA-B*57:01 by abacavir-specific T cell receptors (TCRs). We further show that the high levels of peptide dynamics, and partial dissociation of HLA-B*57:01-bound peptides may allow abacavir direct access to the antigenbinding cleft, and propose conformational dynamics to be a central tenet of all models of HLA-associated drug hypersensitivity. Overall our results suggest structures alone of the HLA-B*57:01-abacavir-peptide complexes are insufficient to account for the molecular basis of AHS.
Results and Discussion
To compare the dynamics of HLA-B*57:01 +/-abacavir, or abacavir analogues, we utilized the three available abacavir-bound HLA-B*57:01 structures (PDB ID 3UPR, 3VRI and 3VRJ), and either removed abacavir or substituted an abacavir analogue into the location of abacavir, and subjected the structures to MD analysis. A summary of all the systems for which MD was performed is provided in Table 1 and the structural components are shown in Figure 1 . antigen-binding groove show that abacavir can bind to HLA-B*57:01 in many similar but distinct conformations. In some cases abacavir and its analogues escape from the binding cleft (Table 2) , with escapes occurring as a result of partial detachment of the peptide at the N-and C-termini, and also from the centre of the binding cleft without any partial detachment of the peptide. One possible explanation for these results is that abacavir and the abacavir analogues do not bind very stably to the MHC-peptide complex. For the abacavir analogues this is plausible given they were modeled into the HLA-B*57:01 structures and, unlike abacavir, have not been proven to bind HLA-B*57:01. This explanation, however, only accounts for the pattern observed for the 3VRI systems, and not for the absence of any escapes in the 3VRJ system, or the fact that abacavir escapes in the 3UPR system while carbovir and guanosine do not. Overall it is difficult to provide a clear rationale for these results in terms of single structural differences. Indeed, it seems likely that all of the abacavir analogues would escape from the binding clefts if the simulations could be run for long enough timescales, and that the observed differences may be due largely to the inherently stochastic nature of MD. observed to interact with these residues. As a consequence, mutations in those residues that introduce a bulkier amino acid, for example Ser116Tyr or Val97Arg, likely create steric clashes which reduce the conformational space available to abacavir when bound to these alleles. As we have shown that abacavir influences complex stability via its effect on the shape of the binding groove, rather than through direct interactions with binding pockets, bulkier residues may destabilize the pMHC-abacavir complex by limiting these effects. 3VRI, and C) 3VRJ. The peptide is shown in sticks (pepV in orange, RVAQ in brick red, LTTK in magenta), HLA-B*57:01 in grey cartoon with the 2 helix omitted for clarity, and abacavir in deep purple sticks. The conformation of abacavir as observed in the corresponding crystallographic structure is also shown in yellow sticks.
Abacavir is highly dynamic when lodged between HLA-B*57:01 and the bound peptide
Our results strongly indicate that the nature and causes of abacavir's hypersensitivity reaction cannot be explained solely through analysis of static structures. Abacavir and the peptides with which it binds vary in conformation to such an extent that any analysis based on the presence or absence of particular steric interactions or hydrogen bonds will almost inevitably fail to identify features which are consistently present in abacavir and only abacavir.
Further, despite performing a combined total of 90 microseconds of MD, no clear structural features or interactions were found to be present in abacavir systems but not any of its analogues, nor were there any such systematic differences between the abacavir analogues as a group and the system with only the peptide.
One outstanding question is whether the three peptides considered in the crystallographic studies bind to HLA-B*57:01 in the absence of abacavir, and also whether they bind in the presence of any of the abacavir analogues. While previous work has indicated that such binding has not been observed 7, 8 , our simulation results fail to indicate that the MHC-peptide-abacavir complex is any more stable than the MHC-peptide or MHC-peptide-analogue complexes. Previous studies have focused on the interaction of the abacavir cyclopropyl group with the Val97 and Ser116 residues unique to HLA-B*57:01 as explaining why only abacavir (which alone of its analogues possesses this cyclopropyl group) and only HLA-B*57:01 (which alone of its similar alleles possesses this residue pair) elicit recognition by T cells 7, 8 . However, our simulations indicate that abacavir does not adopt a consistent conformation with respect to these residues ( Figure 6 ). Conversely, similar forms of interaction are also observed to occur with the abacavir analogues. As such, even if some of these interactions are important for eliciting T cell recognition by abacavir, this can only be a matter of degree, and not due to the binary existence or non-existence of certain interactions. Given the partial peptide detachment observed in our simulations it is possible that, in addition to the altered repertoire model, that the p-i model may also be a driver for AHS. This 'dual' model would account for the observed immediate activation of abacavir-reactive T cells 25 in addition to the delayed abacavir-induced T cell response characteristic of a dependency on conventional antigen-processing pathways 7, 11 . Notably, drug-induced novel peptide conformations are central to both models.
Finally, our results constitute strong evidence against static structure explanations of abacavir-induced hypersensitivity which focus on binary interactions between MHC-peptideabacavir and a T cell response stimulated by a single-conformation peptide, but rather support a mechanism involving selection from amongst dynamical pMHC conformational ensembles.
Concluding remarks
Our MD simulations highlight that HLA-B*57:01-peptide-abacavir crystal structures, which represent static molecular snapshots, do not fully provide an explanation for the strong association of abacavir hypersensitivity with HLA-B*57:01. We show that whether or not abacavir or any of its analogue compounds are present in the HLA-B*57:01 antigen-binding cleft, the peptides exhibit high levels of conformational flexibility. Our MD data does not support the notion that any particular differences in specific conformations or degree of flexibility can account for abacavir's unique immunogenicity. Instead, we propose that hypersensitivity is the result of abacavir altering the equilibrium proportions of different peptide conformations in a manner favourable to TCR binding. Further, we propose the high levels of peptide dynamics, and partial dissociation of HLA-B*57:01-bound peptides, may also allow abacavir direct access to the antigen-binding cleft. Based on our observations it is possible that AHS is driven by both the p-i and altered repertoire hypersensitivity model. We
propose that conformational dynamics is a central tenet of all models of HLA-associated drug hypersensitivity, and should be characterized so as to complement crystallographic studies and in silico docking approaches 26 . The integration of such techniques, alongside the cellular studies and genetic associations reported to drugs, provides for a more comprehensive molecular and mechanistic insights into HLA-associated drug hypersensitivities. Given HLAassociated adverse drug reactions have been reported for over 10 drugs, ranging from anticonvulsants to antibiotics (see 27 for a review), this united approach may accelerate the development of safer and more effective drugs of clinical use for a range of human health conditions.
Materials and Methods

Computational resources
Parameterization of abacavir analogues was performed on Multi-modal Australian ScienceS
Imaging and Visualisation Environment (MASSIVE), while MD simulations were performed on in-house hardware (NVIDIA TITAN X Pascal GPU).
Systems preparation
The coordinates for starting structures of peptide-MHC complexes with abacavir were taken from PDB IDs 3UPR 8 29, 30 , was placed in a rectangular box with a border of at least 10 Å, explicitly solvated with TIP3P water 31 , sodium counter-ions added, and parameterized using the AMBER ff99SB all-atom force field [32] [33] [34] . After an energy minimization stage consisting of at least 10,000 steps, an equilibration protocol was followed in which harmonic positional restraints of 10 kcal Å 2 mol -1 were applied to the protein backbone atoms. The temperature was incrementally increased while keeping volume constant from 0 K to 300 K over the course of 0.5 ns, with Langevin temperature coupling relaxation times of 0.5 ps. After the target temperature was reached, pressure was equilibrated to 1 atm over a further 0.5 ps using the Berendsen algorithm 35 .
Abacavir analogues parameterisation
For each of the abacavir analogues, Gaussian 09 36 was used to optimize its conformation and to calculate its molecular electrostatic potential (ESP). This was done at the HF/6−31++G* level of theory, to allow for polarization effects. The ANTECHAMBER module of AmberTools 12 37 was then used to generate the force field libraries by assigning RESP-fitted charges, as well as Generalized Amber Force Field (GAFF)-derived parameters and atom types 38 for use in Molecular Dynamics (MD) simulations.
Molecular Dynamics (MD)
Following equilibration and parameterization, production MD simulation runs were performed in the NPT ensemble using periodic boundary conditions and a time step of 2 fs. Temperature was maintained at 300 K using the Langevin thermostat with a collision frequency of 2 ps, and electrostatic interactions computed using an 8 Å cutoff radius and the Particle Mesh Ewald method 39 . Pressure was maintained at a constant 1 atm using Berendsen pressure bath coupling with a time coefficient of 0.1 ps 35 . Each simulated system was repeated three times from the same starting structure but with different starting velocities, with each run extending for 2 microseconds.
MD analyses
After the simulations were completed, the three trajectories of each system were concatenated for analysis. Root Mean Square Fluctuation (RMSF) analyses and atomic distance computations were performed using VMD version 1.9.4 40 . Images were rendered using PyMOL 41 . RMSD and RMSF of backbone heavy atoms with respect to their initial structure were calculated every 1 ns, after performing a least-squares fit 42 to the initial structure. RMSF results were reported as the average RMSF per residue backbone throughout simulations.
Clustering analysis was performed using python.
